Who is sponsoring NCT01341353?

NCT01341353 is sponsored by Wuhan University.

What condition does NCT01341353 study?

NCT01341353 studies Atrial Fibrillation.

What drugs are being tested in NCT01341353?

Interventions: catheter ablation, Digaoxin,amiodarone,β receptor antagonist, Calcium Antagonists.

What is the status of NCT01341353?

NCT01341353 is currently UNKNOWN.

Last reviewed 2011-04-21 · How we verify

Atrial Fibrillation Therapy: A Multi-Center Clinical Study

NCT01341353 Phase 4 UNKNOWN

The mainstay of treatment for atrial fibrillation remains pharmacological;however,catheter ablation has increasingly been used over the last decades. The relative merits of each strategy have not been extensively studied. Our study was designed to determine if catheter ablation is a feasible option as first-line therapy for treating patients with symptomatic AF.

Details

Lead sponsor	Wuhan University
Phase	Phase 4
Status	UNKNOWN
Enrolment	1800
Start date	2011-04
Completion	2015-12

Conditions

Atrial Fibrillation

Interventions

catheter ablation
Digaoxin,amiodarone,β receptor antagonist, Calcium Antagonists

Primary outcomes

Number of participants with all-cause death — 3 month
Number of participants with all-cause death — 12 month
Number of participants with all-cause death — 24 month
Number of participants with all-cause death — 36 month
severe blooding complications — 3 month
severe blooding complications — 12 month

Countries

China